Literature DB >> 24900475

A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases.

Hidehisa Iwata1, Hideyuki Oki1, Kengo Okada1, Terufumi Takagi1, Michiko Tawada1, Yasushi Miyazaki1, Shinichi Imamura1, Akira Hori1, J David Lawson2, Mark S Hixon2, Hiroyuki Kimura1, Hiroshi Miki1.   

Abstract

We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.

Entities:  

Keywords:  DFG-out; FBDD; VEGFR2; Yonetani−Theorell Plot; back-to-front; phosphorylation

Year:  2012        PMID: 24900475      PMCID: PMC4025632          DOI: 10.1021/ml3000403

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  A 'rule of three' for fragment-based lead discovery?

Authors:  Miles Congreve; Robin Carr; Chris Murray; Harren Jhoti
Journal:  Drug Discov Today       Date:  2003-10-01       Impact factor: 7.851

3.  Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism.

Authors:  Hidehisa Iwata; Shinichi Imamura; Akira Hori; Mark S Hixon; Hiroyuki Kimura; Hiroshi Miki
Journal:  Biochemistry       Date:  2011-01-10       Impact factor: 3.162

4.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.

Authors:  Jeffrey R Simard; Matthäus Getlik; Christian Grütter; Vijaykumar Pawar; Sabine Wulfert; Matthias Rabiller; Daniel Rauh
Journal:  J Am Chem Soc       Date:  2009-09-23       Impact factor: 15.419

5.  Kinase array design, back to front: biaryl amides.

Authors:  Ian Baldwin; Paul Bamborough; Claudine G Haslam; Suchete S Hunjan; Tim Longstaff; Christopher J Mooney; Shila Patel; Jo Quinn; Don O Somers
Journal:  Bioorg Med Chem Lett       Date:  2008-08-22       Impact factor: 2.823

6.  Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.

Authors:  Hidehisa Iwata; Shinichi Imamura; Akira Hori; Mark S Hixon; Hiroyuki Kimura; Hiroshi Miki
Journal:  Bioorg Med Chem       Date:  2011-08-06       Impact factor: 3.641

Review 7.  Protein kinase biochemistry and drug discovery.

Authors:  Phillip A Schwartz; Brion W Murray
Journal:  Bioorg Chem       Date:  2011-08-03       Impact factor: 5.275

8.  Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.

Authors:  Yuya Oguro; Naoki Miyamoto; Kengo Okada; Terufumi Takagi; Hidehisa Iwata; Yoshiko Awazu; Hiroshi Miki; Akira Hori; Keiji Kamiyama; Shinichi Imamura
Journal:  Bioorg Med Chem       Date:  2010-08-13       Impact factor: 3.641

Review 9.  Do enthalpy and entropy distinguish first in class from best in class?

Authors:  Ernesto Freire
Journal:  Drug Discov Today       Date:  2008-08-26       Impact factor: 7.851

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  7 in total

1.  Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.

Authors:  Christopher W Murray; Valerio Berdini; Ildiko M Buck; Maria E Carr; Anne Cleasby; Joseph E Coyle; Jayne E Curry; James E H Day; Phillip J Day; Keisha Hearn; Aman Iqbal; Lydia Y W Lee; Vanessa Martins; Paul N Mortenson; Joanne M Munck; Lee W Page; Sahil Patel; Susan Roomans; Kirsten Smith; Emiliano Tamanini; Gordon Saxty
Journal:  ACS Med Chem Lett       Date:  2015-06-04       Impact factor: 4.345

2.  Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach.

Authors:  Kingkan Sanphanya; Suvara K Wattanapitayakul; Suwadee Phowichit; Valery V Fokin; Opa Vajragupta
Journal:  Bioorg Med Chem Lett       Date:  2013-03-20       Impact factor: 2.823

3.  Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.

Authors:  Shailima Rampogu; Ayoung Baek; Amir Zeb; Keun Woo Lee
Journal:  BMC Cancer       Date:  2018-03-07       Impact factor: 4.430

4.  Design, Synthesis and Biological Activity Evaluation of S-Substituted 1H-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal Cancer.

Authors:  Marius Mioc; Sorin Avram; Vasile Bercean; Ludovic Kurunczi; Roxana M Ghiulai; Camelia Oprean; Dorina E Coricovac; Cristina Dehelean; Alexandra Mioc; Mihaela Balan-Porcarasu; Calin Tatu; Codruta Soica
Journal:  Front Chem       Date:  2018-08-23       Impact factor: 5.221

5.  Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.

Authors:  Shailima Rampogu; Ayoung Baek; Chanin Park; Shraddha Parate; Saravanan Parameswaran; Yohan Park; Baji Shaik; Ju Hyun Kim; Seok Ju Park; Keun Woo Lee
Journal:  Cells       Date:  2019-03-21       Impact factor: 6.600

6.  Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study.

Authors:  Manar G Salem; Dina M Abu El-Maaty; Yassmina I Mohey El-Deen; Basem H Elesawy; Ahmad El Askary; Asmaa Saleh; Essa M Saied; Mohammed El Behery
Journal:  Molecules       Date:  2022-07-31       Impact factor: 4.927

7.  Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.

Authors:  Xunian Zhou; Grace Gar-Lee Yue; Minghua Liu; Zhili Zuo; Julia Kin-Ming Lee; Mingyue Li; Stephen Kwok-Wing Tsui; Kwok-Pui Fung; Handong Sun; Jianxin Pu; Clara Bik-San Lau
Journal:  Oncotarget       Date:  2016-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.